Posted by SLS on July 3, 2010, at 6:15:33
In reply to Could phenelzine(Nardil) be neuroprotective?, posted by jedi on July 3, 2010, at 2:36:44
MAO inhibition can also protect mitochondria from damage by the free radicals that are produced by the deamination of neurotransmitters.
- Scott
> Hi Guys,
> I've read some posts recently about the possible long term brain damage caused by the hydrazine derivative phenelzine(PLZ). As a user of phenelzine for over a decade, that concerns me. Here is a study that shows the possible neuroprotective effect of phenelzine and it's major metabolite, phenylethylidenehydrazine(PEH).
> Jedi
>
> Summary:
> "Studies on the mechanisms of action and metabolism of PLZ suggest that the clinical application of PLZ should be wider than it already is (e.g. should it be used in post-stroke depression and in Alzheimers disease?) and that analogues of PLZ and PEH should be developed as potential new drugs for treating psychiatric and neurologic disorders, particularity those involving neurodegeneration."
>
> Abstract:
> The monoamine oxidase (MAO)-inhibiting antidepressant
> phenelzine (PLZ) is also used in the treatment of anxiety
> disorders such as panic disorder and social anxiety disorder
> and has been shown to have neuroprotective actions in an
> animal model of transient forebrain ischemia. Phenelzine
> has multiple actions in addition to inhibition of MAO that
> may contribute to its pharmacological and therapeutic
> profile. These actions include inhibition of GABA
> transaminase and elevation of brain levels of GABA, effects
> on functional availability of glutamate, sequestration of
> reactive aldehydes, inhibition of primary amine oxidase
> and effects on brain-derived neurotrophic factor (BDNF). 2-
> Phenylethylidenehydrazine (PEH) has been identified as a
> major metabolite of PLZ and has also been shown to
> elevate brain levels of GABA, to sequester reactive
> aldehydes and to exert neuroprotective effects in a
> transient forebrain ischemia model. The actions of PLZ and
> PEH should be considered when designing future drugs for
> the treatment of psychiatric and neurologic disorders,
> particularly those involving neurodegeneration.
>
> Full text:
> http://www.psikofarmakoloji.org/pdf/20_2_13.pdf
>
The measure of achievement lies not in how high the mountain,
but in how hard the climb.The measure of success lies only in how high one feels he must
climb to get there.
poster:SLS
thread:953079
URL: http://www.dr-bob.org/babble/20100628/msgs/953091.html